Published by Alexander Bueso on 29th July 2022
(Sharecast News) - Analysts at ShoreCap reiterated their 'buy' recommendation for shares of drugs giant AstraZeneca, describing its second quarter top-line growth of 37% year-on-year at constant exchange rates "impressive".
URL: http://www.digitallook.com/dl/news/story/32856875/...